natgillin/translations-raw huggingface dataset:
An orally administrable pharmaceutical composition comprising a,a,a-trifluorothymidine and 5-chloro-6-(2-iminopyrrolidine-1-yl) methyl-2,4 (1H,3H)-pyrimidine dione hydrochloride as active ingredients and a sugar having a critical relative humidity of 85% or more at 25°C as an excipient, and comprising partly pregelatinized starch as a disintegrating agent, wherein the content of the disintegrating agent is from 2 to 16% by mass in the total amount of the pharmaceutical composition. 
Farmaceutska kompozicija koja se može oralno administrirati koja sadrži a,a,a-trifluorotimidin i 5-kloro-6-(2-iminopirolidin-1-il) metil-2,4 (1H,3H)-pirimidin dion hidroklorid kao aktivne sastojke i šećer koji ima kritičnu relativnu vlažnost od 85% ili više na 25°C kao ekscipijens, i koja sadrži djelomično predželatinizirani škrob kao agens za raspadanje, gdje je sadržaj agensa za raspadanje od 2 do 16% mase u ukupnoj količini farmaceutske kompozicije.
an histidine buffering agent (or histidine buffer system); and 
histidinsko pufersko sredstvo (ili histidinski puferski sastav);
A liquid pharmaceutical composition as claimed in any of claims 1 to 5 for use in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and/or juvenile idiopathic arthritis. 
Vodeni farmaceutski pripravak sukladno bilo kojem od patentnih zahtjeva 1 do 12, za uporabu u liječenju reumatoidnog artritisa, psorijatičnog artritisa, ankilozirajućeg spondilitisa, Crohnove bolesti, ulceroznog kolitisa, umjerene do teške kronične psorijaze i/ili idiopatskog artritisa maloljetnika.
R1-R4 are the same or different and represent a hydrogen atom or a group selected from hydroxyl, amino, halo, nitro, cyano, carboxylic acid, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyalkyl, alkoxy, C1-C8 acyl, haloalkyl, preferably R1-R4 represent hydrogen, alkyl, cycloalkyl or haloalkyl, more preferably hydrogen, methyl or CF3; 
i R3 su jednaki ili različiti i predstavljaju atom vodika ili skupinu odabranu iz hidroksil, amino, halo, nitro, cijano, karboksilna kiselina, alkil, cikloalkil, alkenil, alkinil, aril, heteroaril, hidroksialkil, alkoksi, C1-C8 acil, haloalkil, poželjno R2 i R3 predstavljaju vodik, alkil, cikloalkil ili haloalkil, poželjnije vodik, metil ili CF3;
provided that compound of Formula I is not: 
uz uvjet da spoj Formule Ib nije:
The compound according to anyone of claims 1 to 3, wherein R3 represents H. 
Spoj sukladno patentnom zahtjevu 1, gdje R3 predstavlja H.
A pharmaceutical composition comprising a compound according to anyone of claims 1 to 3, and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant. 
Farmaceutski pripravak koji sadrži spoj sukladno bilo kojem od patentnih zahtjeva 1 do 3, i najmanje jedan farmaceutski prihvatljivi nosač, otapalo, ekscipijens i/ili pomoćno sredstvo.
optionally a support material; 
izborno nosivi materijal;
the support material, if present, is selected from porous support materials. 
nosivi materijal, ako je prisutan, se bira između poroznih nosivih materijala.
A method for manufacturing a composite material according to any of claims 1 - 4, said method comprising the steps of 
Postupak proizvodnje kompozitnog materijala u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što se navedeni postupak sastoji u koracima
combining water, amyloid fibrils and activated carbon to obtain a suspension; and 
kombiniranja vode, amiloidnih vlakana i aktivnog ugljena kako bi se dobilo suspenziju; i
filtering said suspension through a porous support material. 
filtriranja navedene suspenzije kroz porozni nosivi materijal.
Use of a composite material according to any of claims 1 - 4, or a filter according to claim 5, for the treatment of water and / or for the recovery of metals. The use of claim 7, wherein 
Upotreba kompozitnog materijala u skladu s bilo kojim od patentnih zahtjeva 1-4, ili filtra u skladu s patentnim zahtjevom 5, naznačena time što su kompozitni materijal ili filtar namijenjeni obradi vode i/ili prikupljanju metala.
providing a composite material according to claim 1-4 and waste water; 
osiguravanja kompozitnog materijala u skladu s patentnim zahtjevom 1-4 i otpadne vode;
contacting said waste water with said composite material, thereby obtaining purified water and loaded composite material; 
stavljanja u kontakt navedene otpadne vode s navedenim kompozitnim materijalom, čime se dobije pročišćenu vodu i opterećeni kompozitni materijal;
separating the purified water from the loaded composite material. 
odvajanja pročišćene vode od opterećenog kompozitnog materijala.
providing a composite material according to claim 1-4 and an aqueous solution containing metal ions; 
osiguravanja kompozitnog materijala u skladu s patentnim zahtjevom 1-4 i vodene otopine koja sadrži metalne ione;
contacting said aqueous solution with the composite material thereby obtaining purified water and loaded composite material; 
stavljanja u kontakt navedene vodene otopine s kompozitnim materijalom, čime se dobije pročišćenu vodu i opterećeni kompozitni materijal;
separating the purified water from the loaded composite material; and 
odvajanja pročišćene vode od opterećenog kompozitnog materijala; i
oxidizing the loaded composite material in an high temperature environment to obtain elemental metals and ash; 
oksidiranja opterećenog kompozitnog materijala u visokotemperaturnom okolišu kako bi se dobilo elementarne metale i pepeo;
■ in step (e), separation is performed by floatation or air floating, optionally with the aid of ultrasound. 
• u koraku (e), razdvajanje se provodi flotacijom ili plutanjem na zraku, moguće uz pomoć ultrazvuka.
A powder composition for the preparation of infusion solutions of antimicrobial preparations soluble in sterile water for injection, 0.45% and 0.9% solution of sodium chloride, characterized in that the powder composition comprises powder sodium chloride and a mechano-chemical activated powder of colloidal silica and sodium chloride, wherein the sodium chloride and the colloidal silica are at a weight ratio of 4.5:1 to 4.5:5 or 9:1 to 9:5, respectively, and the mechano-chemical activated powder is activated by intensive mechanical impact and abrasive action and comprises at least 35% of colloidal silica particles with a size ≤ 5 µm. 
Praškasta smjesa za pripremu infuzijskih otopina antimikrobnih pripravaka topiva u sterilnoj vodi za injektiranje, 0,45 %-tna i 0,9 %-tna otopina natrijevog klorida, naznačena time, da praškasta smjesa sadrži praškasti natrijev klorid i mehanokemijski aktivirani prah koloidnog silicija i natrijevog klorida, pri čemu omjer težine natrijevog klorida i koloidnog silicija iznosi 4,5:1 do 4,5:5 ili 9:1 do 9:5, a mehanokemijski aktivirani prah aktivira se intenzivnim mehaničkim utjecajem i abrazivnim djelovanjem te sadrži najmanje 35 % čestica koloidnog silicija veličine ≤ 5 µm.
A powder composition for the preparation of infusion solutions of antimicrobial preparations soluble in sterile water for injection, 2% and 5% dextrose solution, characterized in that the powder composition comprises dextrose in powder form and a mechano-chemical activated powder of colloidal silica and dextrose, wherein the dextrose and the colloidal silica are at a weight ratio of 20:1 to 20:5 or 50:1 to 50:5, respectively, and the mechano-chemical activated powder is activated by intensive mechanical impact and abrasive action and comprises at least 35% of colloidal silica particles with a size ≤ 5 µm. 
Praškasta smjesa za pripremu infuzijskih otopina antimikrobnih pripravaka topiva u sterilnoj vodi za injektiranje, 2%-tna i 5%-tna otopina dekstroze, naznačena time, da praškasta smjesa sadrži dekstrozu u praškastom obliku i mehanokemijski aktivirani prah koloidnog silicija i dekstroze, pri čemu omjer težine dekstroze i koloidnog silicija iznosi 20:1 do 20:5 ili 50:1 do 50:5, a mehanokemijski aktivirani prah aktivira se intenzivnim mehaničkim utjecajem i abrazivnim djelovanjem te sadrži najmanje 35 % čestica koloidnog silicija veličine ≤ 5 µm.
Powder composition according to claims 1 or 2, characterized in that the colloidal silica consists of silica nanoparticles having an average diameter of from 7 nm to 40 nm joined into microparticles having a size of less than 100 µm. 
Praškasta smjesa prema patentnim zahtjevima 1 ili 2, naznačena time, da se koloidni silicij sastoji od nanočestica silicija s prosječnim promjerom od 7 nm do 40 nm, spojenih u mikročestice veličine manje od 100 µm.
A method for producing a powder composition for the preparation of infusion solutions of antimicrobial preparations, said method including mixing sodium chloride with other components, characterized in that sodium chloride in the powder form is mixed with powder-like colloidal silica at a weight ratio of sodium chloride to colloidal silica of 4.5:1 to 4.5:5 or 9:1 to 9:5, respectively, and the obtained mixture is mechanically activated by impact and abrasive action until the mass fraction of fine-dispersed particles of colloidal silica is increased at least twofold, thereby comprising at least 35% of colloidal silica particles with a size ≤ 5 µm to providing the powder composition comprising a mechano-chemical activated powder of colloidal silica mixed with powder sodium chloride. 
Postupak za proizvodnju praškaste smjese za pripravu infuzijskih otopina antimikrobnih pripravaka; navedeni postupak uključuje miješanje natrijevog klorida s drugim komponentama, naznačen time, da se natrijev klorid u praškastom obliku miješa s koloidnim silicijem praškastog izgleda, u omjeru težine natrijevog klorida i koloidnog silicija koji iznosi 4,5:1 do 4,5:5 ili 9:1 do 9:5, a dobivena smjesa se mehanički aktivira utjecajem i abrazivnim djelovanjem sve dok se masena frakcija fino disperziranih čestica koloidnog silicija ne poveća najmanje dvostruko, pri čemu sadrži najmanje 35 % čestica koloidnog silicija veličine ≤ 5 µm, kako bi se dobila praškasta smjesa koja sadrži mehanokemijski aktivirani prah koloidnog silicija pomiješanog s natrijevim kloridom u prahu.
A method for producing a powder composition for the preparation of infusion solutions of antimicrobial preparations, said method including mixing dextrose with other components, characterized in that dextrose in the powder form is mixed with powder-like colloidal silica at a weight ratio of dextrose to colloidal silica of 20:1 to 20:5 or 50:1 to 50:5, respectively, and the obtained mixture is mechanically activated by impact and abrasive action until the mass fraction of fine-dispersed particles of colloidal silica is increased at least twofold, thereby comprising at least 35% of colloidal silica particles with a size ≤ 5 µm to provide the powder composition comprising a mechano-chemical activated powder of colloidal silica mixed with powder dextrose. 
Postupak za proizvodnju praškaste smjese za pripravu infuzijskih otopina antimikrobnih pripravaka; navedeni postupak uključuje miješanje dekstroze s drugim komponentama, naznačen time, da se dekstroza u praškastom obliku miješa s koloidnim silicijem praškastog izgleda, u omjeru težine dekstroze i koloidnog silicija koji iznosi 20:1 do 20:5 ili 50:1 do 50:5, a dobivena smjesa se mehanički aktivira utjecajem i abrazivnim djelovanjem sve dok se masena frakcija fino disperziranih čestica koloidnog silicija ne poveća najmanje dvostruko, pri čemu sadrži najmanje 35 % čestica koloidnog silicija veličine ≤ 5 µm, kako bi se dobila praškasta smjesa koja sadrži mehanokemijski aktivirani prah koloidnog silicija pomiješanog s dekstrozom u prahu.
Method for producing a powder composition for the preparation of infusion solutions of antimicrobial preparations according to claims 4 or 5, characterized in that the colloidal silica consists of silica nanoparticles having an average diameter of from 7 nm to 40 nm joined into microparticles having a size of less than 100 µm. 
Postupak za proizvodnju praškaste smjese za pripremu infuzijskih otopina antimikrobnih pripravaka prema patentnim zahtjevima 4 ili 5, naznačen time, da se koloidni silicij sastoji od nanočestica silicija s prosječnim promjerom od 7 nm do 40 nm, spojenih u mikročestice veličine manje od 100 µm.
selecting an antimicrobial agent to be injected in a mammal, being the antimicrobial agent in a dry form; 
odabir antimikrobnog agensa koji se injektira u sisavce, koji je antimikrobni agens u suhom obliku;
dissolving the antimicrobial agent in sterile water to provide an antimicrobial solution; 
otapanje antimikrobnog agensa u sterilnoj vodi kako bi se dobila antimikrobna otopina;
mixing the antimicrobial solution with the powder composition by intensively shaken to provide an antimicrobial solution for infusion; and 
miješanje antimikrobne otopine s praškastom smjesom intenzivnom trešnjom, kako bi se dobila antimikrobna otopina za infuziju; i
diluting the prepared antimicrobial infusion solution either in 50 - 200 ml of 0.45% or 0.9% sodium chloride solution, respectively, or in 50 - 200 ml of 2% or 5% dextrose solution, respectively, in accordance with the powder composition comprising powder sodium chloride or powder dextrose, respectively, to provide an antimicrobial infusion solution preparation ready-to-use. 
razrjeđivanje pripremljene antimikrobne infuzijske otopine bilo u 50-200 ml 0,45 %-tne ili 0,9 % -tne otopine natrijevog klorida, ili u 50-200 ml 2 %-tne ili 5 %-tne otopine dekstroze, u skladu s praškastom smjesom koja sadrži natrijev klorid u prahu ili dekstrozu u prahu, kako bi se dobio pripravak antimikrobne otopine za infuziju spreman za uporabu.
Method according to claim 7, characterized in that the antimicrobial infusion solution preparation ready-to-use comprises at least 40% of the antimicrobial agent sorbed at the mechano-chemical activated powder of colloidal silica. 
Postupak prema patentnom zahtjevu 7, naznačen time, da pripravak antimikrobne otopine za infuziju spreman za uporabu sadrži najmanje 40 % antimikrobnog agensa sorbiranog u mehanokemijski aktiviranom prahu koloidnog silicija.
adding a diluent to the fresh human fecal sample to form a diluted sample; 
dodavanju razrjeđivača uzorku ljudske stolice kako bi se dobilo razrijeđeni uzorak;
wherein the diluent includes 30-90 g/L polyethylene glycol in saline; 
gdje razrjeđivač sadrži polietilen-glikol u koncentraciji od 30-90 g/l;
mixing the diluted sample with a mixing apparatus; and 
miješanje razrijeđenog uzorka uređajem za miješanje;
combining a compound of formula (D): with a compound of formula (I): a source of palladium, a tert-butoxide salt, and a phosphine ligand in an aprotic organic solvent to provide the compound of formula (K). 
miješanja spoja s formulom (D): sa spojem s formulom (I): izvorom paladija, soli tert-butoksida, i fosfinskim ligandom u aprotičnom organskom otapalu da se dobije spoj s formulom (K).
The process of claim 1, wherein R2 is and the process further comprises: (c") combining a compound of formula (M): with a tertiary amine base, an organic solvent, and (tetrahydro-2H-pyran-4-yl)methanamine or a salt thereof, to provide the compound of formula (N). 
Postupak prema zahtjevu 1, naznačen time da R2 je i postupak nadalje sadrži: (c") miješanje spoja s formulom (M): s bazom tercijarnog amina, organskim otapalom, i (tetrahidro-2H-piran-4-il)metanaminom ili njegovom soli, da se dobije spoj s formulom (N).
The process of claim 10, wherein a catalytic amount of the compound of formula (J) is used relative to the amount of compound (I), and wherein the catalytic amount of the compound of formula (J) is from about 1 mole percent to about 5 mole percent. 
Postupak prema zahtjevu 10, naznačen time da se koristi katalitička količina spoja s formulom (J) u odnosu na količinu spoja (I), te pri čemu je katalitička količina spoja s formulom (J) od oko 1 molarni postotak do oko 5 molarnih postotaka.
combining a compound of formula (B) with a compound of formula (C): and a tert-butoxide salt in an organic solvent to provide the compound of formula (D). 
miješanje spoja s formulom (B) sa spojem s formulom (C): i soli tert-butoksida u organskom otapalu da se dobije spoj s formulom (D).
The process of claim 13, wherein in step (e) the tert-butoxide salt is selected from the group consisting of sodium tert-butoxide and potassium tert-butoxide. 
Postupak prema zahtjevu 13, naznačen time da je u koraku (e) sol tert-butoksida odabrana iz skupine koja sadrži natrijev tert-butoksid i kalijev tert-butoksid.
combining a C1 to C12 alkyl chloroformate or a di-(C1 to C12 alkyl)dicarbonate with the product of step (f), to provide the compound of formula (C). 
miješanje C1 do C12 alkil kloroformata ili di-(C1 do C12 alkil)dikarbonata s proizvodom iz koraka (f), da se dobije spoj s formulom (C).
combining a compound of formula (E): with dimethylformamide and POCl3 to provide a compound of formula (F): 
miješanje spoja s formulom (E): s dimetilformamidom i POCl3 da se dobije spoj s formulom (F):
combining the compound of formula (F) with a source of palladium and 4-chlorophenylboronic acid in an organic solvent to provide a compound of formula (G): 
miješanje spoja s formulom (F) s izvorom paladija i 4-klorofenilboronskom kiselinom u organskom otapalu da se dobije spoj s formulom (G):
combining the compound of formula (G) with BOC-piperazine and sodium triacetoxyborohydride in an organic solvent to provide a compound of formula (H): and 
miješanje spoja s formulom (G) s BOC-piperazinom i natrijevim triacetoksiborohidridom u organskom otapalu da se dobije spoj s formulom (H): i
combining the compound of formula (H) with hydrochloric acid to provide the compound of formula (I). 
miješanje spoja s formulom (H) s klorovodičnom kiselinom da se dobije spoj s formulom (I).
The process of claim 18, wherein in step (i) the source of palladium is Pd(OAc)2. 
Postupak prema zahtjevu 18, naznačen time da u koraku (i) izvor paladija je Pd(OAc)2.
A method for detecting H. pylori infection in a subject, wherein the method comprises detecting in a sample from the subject an immune response against FliD, wherein the immune response comprises an anti-FliD antibody, wherein the method comprises reacting the sample with FliD or a fragment thereof, wherein the fragment has an amino acid sequence which is long enough so as to identify the fragment to be a fragment of FliD and to exclude that the fragment is a fragment of a protein or polypeptide different from FliD. 
Postupak za otkrivanje H. pylori infekcija kod subjekta, naznačen time da postupak obuhvaća otkrivanje imunološkog odgovora protiv FliD u uzorku subjekta, pri čemu imunološki odgovor sadrži anti-FliD protutijelo, pri čemu postupak obuhvaća reakciju uzorka s FliD ili njegov fragment, gdje fragment ima aminokiselinsku sekvencu koja je dovoljno duga da se identificira fragment koji je fragment FliD i da se isključi da je fragment fragment proteina ili polipeptida koji se razlikuje od FliD.
The method of claim 1, wherein the method comprises reacting the sample with full-length FliD or a fragment thereof, wherein the fragment is a fragment the amino acid sequence of which is shorter than the amino acid sequence of full-length FliD, whereby the fragment is still active as a virulence factor. 
Postupak sukladno zahtjevu 1, naznačen time, da postupak obuhvaća reakciju uzorka s FliD punom dužinom ili njegovim fragmentom, pri čemu je fragment fragment čija je aminokiselinska sekvenca kraća od aminokiselinske sekvence FliD pune duljine, pri čemu je fragment je još uvijek aktivan kao faktor virulencije.
The method of claim 1 or 2, wherein the anti-FliD antibody is an IgG antibody and/or an IgA antibody. 
Postupak sukladno zahtjevu 1 ili 2, naznačen time, da je anti-FliD protutijelo IgG protutijelo i/ili IgA protutijelo.
The method of any one of claims 1 to 2, wherein the detection occurs by means of an ELISA, a lateral flow assay or a line assay. 
Postupak sukladno bilo kojem od zahtjeva 1 do 3, pri čemu se detekcija izvodi pomoću ELISE, testa sa bočnim protokom ili linijskog testa.
The method of any one of claims 1 to 5, wherein the sample is selected from the group consisting of blood serum, blood plasma, whole blood and stool. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da je uzorak odabran iz skupine koja se sastoji od krvnog seruma, krvne plazme, pune krvi i stolice
Use of a kit comprising FliD or a fragment thereof and at least one further constituent, in a method of any one of claims 1 to 6, wherein the fragment has an amino acid sequence which is long enough so as to identify the fragment to be a fragment of FliD and to exclude that the fragment is a fragment of a protein or polypeptide different from FliD, and wherein the at least one further constituent is selected from the group consisting of a buffer, a solid phase and an instruction leaflet. 
Uporaba kompleta koji sadrži FliD ili njegov fragment i najmanje jedan daljnji sastojak, u postupku sukladno bilo kojem od zahtjeva 1 do 6, naznačen time da fragment ima aminokiselinsku sekvencu koja je dovoljno duga da se identificira fragment koji je fragment FliD i isključi da je fragment fragment proteina ili polipeptida koji je različit od FliD i pri čemu je barem jedan daljnji sastojak odabran iz skupine koja se sastoji od pufera, čvrste faze i upute za uporabu.
The use of claim 7, wherein the kit comprises full-length FliD or a fragment thereof, wherein the fragment is a fragment the amino acid sequence of which is shorter than the amino acid sequence of full-length FliD, whereby the fragment is still active as a virulence factor. 
Uporaba sukladno zahtjevu 7, naznačena time, da komplet sadrži FliD pune duljine ili njegov fragment, pri čemu je fragment fragment čija je aminokiselinska sekvenca kraća od aminokiselinske sekvence pune duljine FliD, pri čemu je fragment još uvijek aktivan kao čimbenik virulencije.
A kit suitable for use in a method of any one of claims 1 to 6, said kit comprising full-length FliD or a fragment thereof and at least one further constituent, wherein the fragment is a fragment the amino acid sequence of which is shorter than the amino acid sequence of full-length FliD, whereby the fragment is still active as a virulence factor, and wherein the at least one further constituent is selected from the group consisting of a buffer, a solid phase and an instruction leaflet. 
Komplet pogodan za uporabu u postupku sukladno bilo kojem od patentnih zahtjeva 1 do 6, naznačena time, da navedeni komplet sadrži FliD pune duljine ili njegov fragment i barem jedan daljnji sastojak, pri čemu je fragment fragment čija je aminokiselinska sekvenca kraća od aminokiselinske sekvenca FliD pune duljine, pri čemu je fragment još uvijek aktivan kao faktor virulencije, i pri čemu je najmanje jedan daljnji sastojak odabran iz skupine koja se sastoji od pufera, čvrste faze i uputa za uporabu.
is hydrogen, hydroxy, or alkyl; and R3 is alkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; or R2 and R3 together with the nitrogen to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with 1, 2, 3, or 4 R8; and wherein the -NR2R3 heterocycloalkyl is not morpholinyl; 
je vodik, hidroksi, ili alkil; i R3 je alkil, aminoalkil, alkilaminoalkil, ili dialkilaminoalkil; ili R2 i R3 zajedno s dušikom na koji su oni vezani tvore 3-10 člani heterocikloalkilni prsten koji je proizvoljno supstituiran s 1, 2, 3, ili 4 R8; i pri čemu -NR2R3 heterocikloalkil nije morfolinil;